Pancreatic Cancer Research

ResearcherRoyal Marsden NHS Foundation TrustActive in the last 2 years

Naureen Starling

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1496-6792; OpenAlex author ID A5004047300. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
45
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 11

  1. Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma-UK Tertiary Cancer Centre Experience. Co-author DOI 10.3390/cancers18101597↗
  2. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE … Co-author DOI 10.1016/j.annonc.2021.01.070↗
  3. Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Co-author DOI 10.1038/s41467-021-27099-6↗
  4. Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1155/2019/7135437↗
  5. Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. Last author DOI 10.1177/1758835918816281↗
  6. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing … Co-author DOI 10.1007/s10637-017-0473-9↗
  7. Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy. Last author DOI 10.1177/1758834016688816↗
  8. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU… Co-author DOI 10.18632/oncotarget.7208↗
  9. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets. Last author DOI 10.1016/j.critrevonc.2015.03.008↗
  10. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancre… First author DOI 10.1016/j.ejca.2014.02.003↗
  11. A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. Co-author DOI 10.1093/annonc/mdr317↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David Cunningham · 8 shared papers, 2012–2026 · strength 0.77
  2. Ian Chau · 5 shared papers, 2012–2026 · strength 0.44
  3. Kate Young · 3 shared papers, 2017–2021 · strength 0.32
  4. Katharine L. Aitken · 1 shared paper, 2026 · strength 0.24
  5. Ricky Harminder Bhogal · 1 shared paper, 2026 · strength 0.24
  6. Kai Tai Derek Yeung · 1 shared paper, 2026 · strength 0.24
  7. David J. Watkins · 4 shared papers, 2012–2021 · strength 0.20
  8. Francesco Sclafani · 2 shared papers, 2015–2021 · strength 0.16
  9. Teresa Mercade Macarulla · 2 shared papers, 2017–2021 · strength 0.16
  10. Caroline Fong · 1 shared paper, 2019 · strength 0.14
  11. Matteo Fassan · 2 shared papers, 2016–2021 · strength 0.13
  12. Chiara Braconi · 2 shared papers, 2016–2021 · strength 0.13
  13. Emma Kipps · 1 shared paper, 2017 · strength 0.12
  14. Lisa M. Coussens · 1 shared paper, 2021 · strength 0.10
  15. Andrew Eugene Hendifar · 1 shared paper, 2021 · strength 0.10
  16. Josep M. Tabernero · 1 shared paper, 2021 · strength 0.10
  17. Rocio García‐Carbonero · 1 shared paper, 2021 · strength 0.10
  18. Lawrence H. Fong · 1 shared paper, 2021 · strength 0.10
  19. Sara Lonardi · 1 shared paper, 2021 · strength 0.10
  20. Joan Maurel · 1 shared paper, 2021 · strength 0.10
  21. Do‐Youn Oh · 1 shared paper, 2021 · strength 0.10
  22. Dirk Waldschmidt · 1 shared paper, 2021 · strength 0.10
  23. Michele Reni · 1 shared paper, 2021 · strength 0.10
  24. Jean‐Baptiste Bachet · 1 shared paper, 2021 · strength 0.10
  25. Margaret A. Tempero · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.